Jazz Pharmaceuticals Public Limited Company director Bruce Cozadd filed a Form 144 notice on November 6, 2026, disclosing a proposed sale of 68,808 common shares on NASDAQ following a stock option exercise.

Key Highlights

  • Proposed sale: Bruce Cozadd, listed as a Director, intends to sell 68,808 shares of Jazz Pharmaceuticals common stock.
  • Aggregate market value: The proposed sale carries an aggregate market value of $16,235,515.95, according to the filing.
  • Acquisition method: The 68,808 shares were acquired on November 6, 2026, via a stock option exercise from the issuer, with payment made in cash on the same date.
  • Shares outstanding: The filing states 64,189,052 shares of common stock were outstanding at the time of notice.
  • Broker named: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004 is identified as the broker for the proposed sale.
  • Prior sales in past three months: Cozadd sold 6,000 shares on November 2, 2026 (gross proceeds $1,295,040.00), 6,000 shares on October 1, 2026 (gross proceeds $1,381,980.00), 6,000 shares on September 1, 2026 (gross proceeds $1,500,780.00), and 1,219 shares on August 31, 2026 (gross proceeds $294,281.21).

Cozadd's Proposed Sale Details and Recent Transaction History at Jazz Pharmaceuticals

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Bruce Cozadd, a Director of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ), proposed to sell 68,808 shares of the company's common stock on November 6, 2026. The filing identifies the approximate date of sale as November 6, 2026, and names NASDAQ as the securities exchange. The aggregate market value of the shares to be sold is listed as $16,235,515.95.

The filing discloses that the shares proposed for sale were acquired on November 6, 2026, through a stock option exercise from the issuer, with full cash payment made on the same date. As of the notice date, the filing reports 64,189,052 shares of common stock outstanding for Jazz Pharmaceuticals Public Limited Company, which is headquartered at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.

The filing also details Cozadd's sales of Jazz Pharmaceuticals common stock over the preceding three months. Those transactions consisted of 6,000 shares sold on November 2, 2026, generating gross proceeds of $1,295,040.00; 6,000 shares sold on October 1, 2026, generating gross proceeds of $1,381,980.00; 6,000 shares sold on September 1, 2026, generating gross proceeds of $1,500,780.00; and 1,219 shares sold on August 31, 2026, generating gross proceeds of $294,281.21. The combined prior-period sales total 19,219 shares across four transactions.

What Was Disclosed

Bruce Cozadd, a Director of Jazz Pharmaceuticals Public Limited Company, filed a Form 144 on November 6, 2026, disclosing a proposed sale of 68,808 common shares acquired via stock option exercise, with an aggregate market value of $16,235,515.95, to be executed on NASDAQ.